2024-09-01 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** Amgen (AMGN) is a leading biotechnology company focused on developing, manufacturing, and delivering innovative therapies for serious illnesses.

**Performance Analysis:**

1. **Relative Performance:** AMGN has underperformed the S&P 500 (VOO) in the past, with a cumulative return of 58.57% compared to VOO's 89.66%. This represents a current underperformance of 31.09%, placing it at the 46.06% percentile of its historical performance range.

2. **Recent Price Action:** The stock is currently trading at $333.83, slightly above its 5-day moving average ($329.61), but below its 20-day ($325.69) and 60-day ($321.37) moving averages. This suggests a potential short-term weakness compared to the longer-term trend.

3. **Technical Indicators:** 
    * **RSI (68.97):** The RSI indicates the stock is currently in the overbought territory, suggesting potential short-term price correction. 
    * **PPO (0.17):** The PPO is positive, suggesting a bullish momentum, but the recent decline in the Relative Divergence (-12.38) indicates a weakening of that momentum. 
    * **Expected Return (7.55%):** This indicates a potential for further upside growth based on current investment levels, but with the current overbought condition, this might be a conservative estimate.

4. **Recent Earnings and Outlook:** 
    | Date      | EPS      | Revenue     |
    |-----------|----------|-------------|
    | 2024-08-07| 1.39     | 8.39 B$     |
    | 2024-05-03| -0.21    | 7.45 B$     |
    | 2023-10-31| 3.23     | 6.90 B$     |
    | 2023-08-04| 2.58     | 6.99 B$     |
    | 2024-08-07| 2.58     | 6.99 B$     |

    The most recent earnings report (2024-08-07) showed a strong EPS beat, exceeding estimates by a significant margin. This demonstrates the company's continued growth and profitability despite the current market conditions. 

**Overall Analysis:**

AMGN shows strong recent earnings performance, supporting further growth potential. However, the stock is currently overbought and exhibiting signs of weakening momentum. The recent underperformance compared to the S&P 500 and potential short-term price correction may warrant caution before making investment decisions. Investors should carefully consider the current market conditions and individual risk tolerance before investing. 
